Efficacy and safety of immune checkpoint blockade for brain metastases.
作者信息
Harary Maya, Reardon David A, Iorgulescu J Bryan
机构信息
Harvard Medical School, Boston, MA, 02215, USA.
Department of Neurosurgery, Computational Neuroscience Outcomes Center, Brigham & Women's Hospital, Boston, MA, 02215, USA.
出版信息
CNS Oncol. 2019 Jun;8(2):CNS33. doi: 10.2217/cns-2018-0018. Epub 2019 Mar 11.
Abstract
摘要
相似文献
1
Efficacy and safety of immune checkpoint blockade for brain metastases.
CNS Oncol. 2019 Jun;8(2):CNS33. doi: 10.2217/cns-2018-0018. Epub 2019 Mar 11.
2
Atypical autoimmune adverse effects with checkpoint blockade therapies.
Ann Oncol. 2017 Feb 1;28(2):206-207. doi: 10.1093/annonc/mdw658.
3
Immune checkpoint inhibitors.
J Cell Biol. 2019 Mar 4;218(3):740-741. doi: 10.1083/jcb.201810035. Epub 2019 Feb 13.
4
Checkpoint blockade after kidney transplantation.
Eur J Cancer. 2018 Jun;96:111-114. doi: 10.1016/j.ejca.2018.03.019. Epub 2018 Apr 26.
5
Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies.
Ann Oncol. 2017 Jan 1;28(1):57-74. doi: 10.1093/annonc/mdw534.
6
Recent advances in the clinical development of immune checkpoint blockade therapy.
Cell Oncol (Dordr). 2019 Oct;42(5):609-626. doi: 10.1007/s13402-019-00456-w. Epub 2019 Jun 14.
7
Targeting Multiple Receptors to Increase Checkpoint Blockade Efficacy.
Int J Mol Sci. 2019 Jan 4;20(1):158. doi: 10.3390/ijms20010158.
8
The next generation of immunotherapy: keeping lung cancer in check.
J Hematol Oncol. 2017 Apr 24;10(1):87. doi: 10.1186/s13045-017-0456-5.
9
Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
Int Immunopharmacol. 2018 Sep;62:29-39. doi: 10.1016/j.intimp.2018.06.001. Epub 2018 Jul 2.
10
Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic.
Cancer Treat Rev. 2020 Sep;89:102067. doi: 10.1016/j.ctrv.2020.102067. Epub 2020 Jul 7.
引用本文的文献
1
Antigen presentation deficiency, mesenchymal differentiation, and resistance to immunotherapy in the murine syngeneic CT2A tumor model.
Front Immunol. 2023 Dec 28;14:1297932. doi: 10.3389/fimmu.2023.1297932. eCollection 2023.
2
High-dose bevacizumab for radiation-induced brain necrosis: a case report.
CNS Oncol. 2023 Sep 1;12(3):CNS98. doi: 10.2217/cns-2023-0002. Epub 2023 May 4.
3
Use of First-Line Immune Checkpoint Inhibitors and Association With Overall Survival Among Patients With Metastatic Melanoma in the Anti-PD-1 Era.
JAMA Netw Open. 2022 Aug 1;5(8):e2225459. doi: 10.1001/jamanetworkopen.2022.25459.
4
Research Progress on Radiotherapy Combined with Immunotherapy for Associated Pneumonitis During Treatment of Non-Small Cell Lung Cancer.
Cancer Manag Res. 2022 Aug 13;14:2469-2483. doi: 10.2147/CMAR.S374648. eCollection 2022.
5
MCP-1/CCR2 axis inhibition sensitizes the brain microenvironment against melanoma brain metastasis progression.
JCI Insight. 2022 Sep 8;7(17):e154804. doi: 10.1172/jci.insight.154804.
6
Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies.
J Immunother Cancer. 2022 Jan;10(1). doi: 10.1136/jitc-2021-003024.
7
Harnessing nanomedicine for enhanced immunotherapy for breast cancer brain metastases.
Drug Deliv Transl Res. 2021 Dec;11(6):2344-2370. doi: 10.1007/s13346-021-01039-9. Epub 2021 Oct 30.
8
Association between PD-L1 expression and initial brain metastasis in patients with non-small cell lung cancer and its clinical implications.
Thorac Cancer. 2021 Aug;12(15):2143-2150. doi: 10.1111/1759-7714.14006. Epub 2021 Jun 13.
9
Efficacy of immune-checkpoint inhibitors in advanced non-small cell lung cancer patients with different metastases.
Ann Transl Med. 2021 Jan;9(1):34. doi: 10.21037/atm-20-1471.
10
Oligoprogressive Non-Small-Cell Lung Cancer under Treatment with PD-(L)1 Inhibitors.
Cancers (Basel). 2020 Apr 23;12(4):1046. doi: 10.3390/cancers12041046.
本文引用的文献
1
Acquired mechanisms of immune escape in cancer following immunotherapy.
Genome Med. 2018 Nov 22;10(1):87. doi: 10.1186/s13073-018-0598-2.
2
Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial.
J Clin Oncol. 2019 Jan 1;37(1):52-60. doi: 10.1200/JCO.18.00204. Epub 2018 Nov 8.
3
Treatment of brain metastases with stereotactic radiosurgery and immune checkpoint inhibitors: An international meta-analysis of individual patient data.
Radiother Oncol. 2019 Jan;130:104-112. doi: 10.1016/j.radonc.2018.08.025. Epub 2018 Sep 18.
4
Management of metastatic melanoma: improved survival in a national cohort following the approvals of checkpoint blockade immunotherapies and targeted therapies.
Cancer Immunol Immunother. 2018 Dec;67(12):1833-1844. doi: 10.1007/s00262-018-2241-x. Epub 2018 Sep 6.
5
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.
N Engl J Med. 2018 Aug 23;379(8):722-730. doi: 10.1056/NEJMoa1805453.
6
Improved Risk-Adjusted Survival for Melanoma Brain Metastases in the Era of Checkpoint Blockade Immunotherapies: Results from a National Cohort.
Cancer Immunol Res. 2018 Sep;6(9):1039-1045. doi: 10.1158/2326-6066.CIR-18-0067. Epub 2018 Jul 12.
7
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme.
BJU Int. 2019 Jan;123(1):98-105. doi: 10.1111/bju.14461. Epub 2018 Jul 23.
8
Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.
Lancet Oncol. 2018 May;19(5):672-681. doi: 10.1016/S1470-2045(18)30139-6. Epub 2018 Mar 27.
9
Cancer immunotherapy using checkpoint blockade.
Science. 2018 Mar 23;359(6382):1350-1355. doi: 10.1126/science.aar4060. Epub 2018 Mar 22.
10
Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
Int J Radiat Oncol Biol Phys. 2018 Mar 15;100(4):916-925. doi: 10.1016/j.ijrobp.2017.11.041. Epub 2017 Dec 5.
Zotero 插件